Earlier this year, patients treated by an AI chatbot for some common mental health challenges got better. This was significant because the patients were part of the first randomized and controlled trial for this type of AI intervention. 

“Just as medicine has its own language, so does business," two surgeons explained in a new editorial. 

Even TAVR patients not treated using transfemoral access can typically go home the very next day. 

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

The Joint Commission is partnering with the Coalition for Health AI to scale AI accountability. The project will supply more than 80% of U.S. provider orgs with gameplans, toolkits and overall guidance. 

To maximize returns on AI investments, healthcare organizations should align AI initiatives with core competencies. The effort should focus on optimizing experiences for workforces as well as patients. 

Overall, 30-day outcomes were not significantly different for hospitals after being acquired by a private equity firm. However, the study’s authors did identify trends that suggest there may be a drop in the quality of care. 

On the technical and ethical planes, the National Academy of Medicine’s fresh guidance may represent the best way yet to ensure alignment of healthcare AI stakeholders.